Biotech Leaders Surge to 52-Week Highs

(RTTNews) – On July 14 2026, these biotech stocks reached a 52‑week high, driven by capital‑raising offerings and expanded business initiatives.

The Oncology Institute Inc. (TOI)

The Oncology Institute, Inc. (TOI) operates a specialty pharmacy and offers patients services including assistance with clinical trial enrollment. Its shares climbed to a 52‑week high of $6.66 on Tuesday.

The firm recently satisfied a $86 million senior convertible note by settling it through a financing agreement with OrbiMed, which also provided new credit facilities.

Earlier this year, the company posted first‑quarter revenue of $147.4 million, a 41% increase year‑over‑year. It projects full‑year revenue of $630 million to $650 million for 2026.

Inhibikase Therapeutics Inc. (IKT)

Inhibikase Therapeutics, Inc. (IKT) is a clinical‑stage pharmaceutical firm developing therapies for cardiopulmonary conditions, especially pulmonary arterial hypertension (PAH). Its shares rose more than 5% to $2.36, marking a 52‑week high during intraday trading on Tuesday.

The company’s lead candidate, IKT‑001, is an oral formulation of imatinib mesylate for PAH and has received Orphan Drug designation from the U.S. Food and Drug Administration. It is presently in the global Phase 3 IMPROVE‑PAH trial, which enrolled its first patient in April 2026.

On Tuesday, the company disclosed the sale of $50 million of shares via an at‑the‑market offering, with proceeds slated to advance the Phase 3 study.

Alto Neuroscience Inc. (ANRO)

Alto Neuroscience, a clinical‑stage biopharma company advancing precision therapies for neuropsychiatric disorders, saw its shares climb to a 52‑week high of $28.85 on Tuesday.

Its lead candidates are ALTO‑207 for treatment‑resistant depression (TRD) and ALTO‑300 for major depressive disorder (MDD), both in Phase 2 trials to verify efficacy in biomarker‑positive patients. The pipeline also includes ALTO‑100 for bipolar depression, ALTO‑101 for schizophrenia, and ALTO‑203 and ALTO‑202 for MDD.

On Monday, the company announced a registered direct offering priced to raise approximately $100 million, with proceeds earmarked for advancing ALTO‑207 and accelerating its development toward a Phase 3 trial.

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV) provides a range of health‑coverage services across Medicare, Medicaid and the Federal Employee Program in the United States. Its share price touched a 52‑week high of $434.38 in Tuesday’s trading.

Elevance serves roughly 45.4 million medical members and offers Carelon services, including CarelonRx. Its affiliated health companies support about 105 million consumers with comprehensive medical, pharmacy, behavioral, clinical, home‑health and complex‑care solutions.

The company projects adjusted diluted earnings per share of at least $26.75 for the full year 2026.

Privia Health Group Inc. (PRVA)

Privia Health Group, Inc. (PRVA) is a physician‑enabled provider that creates scaled primary‑care networks and operates under physician leadership. Its shares rose to a 52‑week high of $28.30 on Tuesday.

The firm serves roughly 5,500 physicians across 1,300 practices in 25 states, recently adding a practice in New Jersey.

Privia projects GAAP revenue for 2026 to be $2.35 billion–$2.45 billion, up from $2.12 billion reported for 2025.

Source link